-
n this issue: Results from a Phase 3 study of dabigatran, intensive lipid-lowering in CVD, H1N1 vaccine dosing and efficacy, and FDA Actions.
-
One-year mortality post-severe sepsis and septic shock was significantly reduced after implementation of an early goal-directed therapy protocol for sepsis in a large urban emergency department.
-
This multicenter, unblinded, randomized trial demonstrated that prone positioning was not associated with a mortality benefit in patients with ARDS, including subgroups with moderate and severe hypoxemia.
-
Patients who adhered to prescribed anti-hypertensive medication experienced a significantly decreased risk of acute cardiovascular events, yet only 6 months after diagnosis, only 8.1% of patients were classified as having high adherence, 40.5% demonstrated intermediate adherence, and 51.4% demonstrated low adherence to prescribed medication regimens.
-
Do children < 1-year-old actually develop diarrhea due to C. difficile? What should be the patient age cutoff below which laboratories should reject any stools for C. difficile testing? How will the new state-of-the-art molecular tests influence the interpretation of results in children?
-
-
Generally, families of critical care patients are not actively involved in patient care in a consistent or meaningful way.
-
This large-scale clinical trial of exogenous surfactant administration in adult patients with acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) used internationally accepted diagnostic criteria and the ARDS Net lung-protective ventilation protocol in all patients.
-
In an attempt to reproduce the situation in which a covering physician is called urgently to a patient's bedside because of a ventilator-related problem, this laboratory study sought to determine how readily intensivists could operate new-generation ICU mechanical ventilators with which they were not personally familiar.
-
In this issue: Results from a Phase 3 study of dabigatran, intensive lipid-lowering in CVD, H1N1 vaccine dosing and efficacy, and FDA Actions.
